Indication
For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):
• in patients with haemolysis with clinical symptom(s) indicative of high disease activity
• in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.
Medicine details
- Medicine name:
- ravulizumab (Ultomiris)
- SMC ID:
- SMC2305
- Pharmaceutical company
- Alexion Pharma UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- Q1 2021
- SMC meeting date:
- Q1 2021
- Patient group submission deadline:
- 02 November 2020